Abiopharma

🔍 Kalb Michael Wayne (Executive)

Company: CATALYST PHARMACEUTICALS, INC. (CPRX)

Report Date: 2026-01-05

Detailed Transactions and Holdings:

• Acquired 7,139 shares of Common Stock, par value $0.001 per share (Direct)
  Date: 2026-01-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 15,745.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,080 shares of Common Stock, par value $0.001 per share (Direct)
  Date: 2026-01-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 13,665.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 7,139 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 632,903.00 | transaction_form_type: 4 | Footnotes: F1, F3, F4

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
• F2: Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock.
• F3: Derivative securities vest in equal tranches, 1/5th on January 1, 2025, 1/5th on January 1, 2026, 1/5th on January 1, 2027, 1/5th on January 1, 2028, and 1/5th on January 1, 2029.
• F4: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The second tranche of shares was delivered on January 5, 2026.